ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,145.02
-0.18%
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs Yen
156.955
0.00%
Brent Oil
81.965
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Seres Therapeutics Inc (MCRB)

  7. Seres Therapeutics Inc (MCRB) ニュース

MCRB

Seres Therapeutics (MCRB)

Seres Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MCRB
日付受信時刻ニュースソース見出しコード企業名
2024/05/1809 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/05/1809 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/05/1809 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/05/1809 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/05/1809 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/05/0823 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MCRBSeres Therapeutics Inc
2024/05/0820 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
2024/05/0820 : 00Business WireSeres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
2024/05/0806 : 18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
2024/05/0705 : 01Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
2024/05/0622 : 30Business WireSeres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024NASDAQ:MCRBSeres Therapeutics Inc
2024/04/0920 : 00Business WireSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTNASDAQ:MCRBSeres Therapeutics Inc
2024/03/2820 : 00Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
2024/03/1920 : 00Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
2024/03/0600 : 18Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
2024/03/0600 : 13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MCRBSeres Therapeutics Inc
2024/03/0521 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
2024/03/0521 : 00Business WireSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
2024/03/0520 : 05IH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:MCRBSeres Therapeutics Inc
2024/02/2821 : 00Business WireSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024NASDAQ:MCRBSeres Therapeutics Inc
2024/02/2721 : 00Business WireSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
2024/02/2621 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
2024/02/2621 : 00Business WireSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzNASDAQ:MCRBSeres Therapeutics Inc
2024/02/2406 : 05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
2024/02/1711 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/02/1711 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/02/1711 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/02/1711 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/02/1711 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
2024/02/1711 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MCRB

最近閲覧した銘柄

NYSE
NKE
Nike
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
FX
USDJPY
US Dollar vs Yen
NYSE
MRK
Merck
FX
USDEUR
US Dollar vs Euro
NYSE
XOM
Exxon Mobil
NYSE
VZ
Verizon Communications
CCOM
US100
US Tech 100
NYSE
BAC
Bank of America
AMEX
XLV
Health Care Select Sector
USI
USTECH100
US Tech 100
NYSE
DIS
Walt Disney
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有